Belgian Biopharma MRM Health Secures €55 Million to Drive Microbiome Therapeutic Innovation
September 7, 2025, 9:31 am
MRM Health, a Belgian biopharma, closed a €55 million Series B financing round. This capital accelerates groundbreaking microbiome-based therapeutics. Lead program MH002 targets ulcerative colitis, entering Phase 2b trials. The proprietary CORAL platform drives development of Live Biotherapeutic Products. Funds will advance new programs in immune-oncology and inflammation. Strategic partnerships, including Biocodex, bolster manufacturing. This fuels a new era of treatments for chronic inflammatory conditions, addressing critical unmet patient needs worldwide. The move solidifies MRM Health's leadership in the rapidly evolving microbiome sector.
Ghent, Belgium. MRM Health, a clinical-stage biopharmaceutical company, announced a significant financial milestone. It secured €55 million (approximately US$64 million) in Series B funding. This investment propels its innovative pipeline. It focuses on microbiome-based therapeutics. These target inflammatory diseases and immune-oncology.
French pharmaceutical leader Biocodex spearheaded the round. German investor ATHOS made a strong commitment. New investor BNP Paribas Fortis Private Equity joined. Existing backers also participated. SFPIM, Ackermans & van Haaren, OMX Europe Venture Fund, Qbic II, and VIB all reaffirmed their support. This capital infusion validates MRM Health’s pioneering work. It underscores deep belief in its unique technological approach.
A core use for the new funds targets MH002. This is MRM Health's lead program. It treats mild-to-moderate ulcerative colitis patients. MH002 now advances to a pivotal Phase 2b clinical trial. It represents the most advanced Live Biotherapeutic Product (LBP) of its kind. Its design employs a rationally selected combination of disease-specific bacteria. Earlier Phase 2a trials demonstrated both safety and initial efficacy. Positive data emerged for both ulcerative colitis and pouchitis. Pouchitis is a rare inflammatory condition. Both diseases fall under Inflammatory Bowel Diseases (IBD). Current treatments often fail to provide lasting relief. Patients face chronic suffering. MH002 offers a novel, targeted therapeutic pathway.
MRM Health's proprietary CORAL platform defines its innovation. This technology transforms live microbial therapeutics development. It combines specific bacterial strains. A unique optimization process creates synergistic consortia. These consortia are potent. They are resilient. They are scalable. The platform enhances efficacy. It streamlines complex microbial therapy manufacturing. This provides a crucial competitive advantage. It allows for the production of complete consortia as a single drug substance. This efficiency is critical for regulatory approval and patient access.
Beyond MH002, MRM Health plans robust pipeline expansion. Two novel microbial consortia programs will rapidly advance. One targets general inflammation. The other aims to boost immune-oncology treatment efficacy. Both programs aim for Investigational New Drug (IND) approval. This signifies a readiness for human trials. The company also seeks to broaden its LBP portfolio. Strategic partnerships will facilitate this growth. These partnerships span both human and animal health sectors.
A key strategic collaboration now formalizes with Biocodex. This partnership focuses on dual objectives. First, it develops novel therapeutic assets. Second, it builds scalable manufacturing capabilities for LBPs. This alliance will generate significant additional non-dilutive funding. It further strengthens MRM Health's operational foundation. Such strategic alliances are indispensable for long-term success. They distribute risk and leverage complementary expertise.
The human microbiome represents a frontier in medicine. Trillions of microorganisms inhabit the gut. Their delicate balance profoundly impacts health. Imbalances, or dysbiosis, link to a spectrum of chronic conditions. These include autoimmune disorders, metabolic diseases, and various cancers. MRM Health meticulously leverages this scientific understanding. It engineers precise microbial consortia. These aim to restore healthy balance. They directly address disease-driving mechanisms at their source.
MRM Health positions itself at the forefront of this new medical era. Its CORAL technology has reached maturity. This enables effective development, scaling, and commercialization of live biotherapeutics. These therapies target major chronic inflammatory diseases. Millions of patients globally experience high unmet medical needs. Current treatment options often present severe side effects. They may also lose effectiveness over time. This funding empowers MRM Health to deliver significant, lasting patient impact.
The company's leadership expanded. New members joined the Board of Directors. Jean-Patrick Hennebelle represents Biocodex. Julian Zachmann represents ATHOS. Goedele Ertveldt represents SFPIM. These additions bring extensive industry experience. They offer vital strategic guidance. The expanded board will steer MRM Health. It aims to advance its pipeline robustly. It will deliver this novel class of innovative therapeutics to patients worldwide.
The global market for microbiome therapeutics experiences rapid growth. Investors increasingly recognize its transformative potential. Successful clinical trials validate the underlying science. MRM Health’s approach stands out. Its platform ensures precise, scalable, and cost-effective production. This overcomes a major hurdle in LBP development. The company is not merely exploring. It is actively building viable, commercial solutions.
This substantial funding represents a profound vote of confidence. It acknowledges years of dedicated scientific research. It unlocks the critical next phase of development. MRM Health moves significantly closer to market introduction. It strives to bring transformative therapies to those in need. The company aims for global health impact. Its vision is clear: harness the power of the microbiome for a healthier future. This is a pivotal moment for personalized medicine.
Ghent, Belgium. MRM Health, a clinical-stage biopharmaceutical company, announced a significant financial milestone. It secured €55 million (approximately US$64 million) in Series B funding. This investment propels its innovative pipeline. It focuses on microbiome-based therapeutics. These target inflammatory diseases and immune-oncology.
French pharmaceutical leader Biocodex spearheaded the round. German investor ATHOS made a strong commitment. New investor BNP Paribas Fortis Private Equity joined. Existing backers also participated. SFPIM, Ackermans & van Haaren, OMX Europe Venture Fund, Qbic II, and VIB all reaffirmed their support. This capital infusion validates MRM Health’s pioneering work. It underscores deep belief in its unique technological approach.
A core use for the new funds targets MH002. This is MRM Health's lead program. It treats mild-to-moderate ulcerative colitis patients. MH002 now advances to a pivotal Phase 2b clinical trial. It represents the most advanced Live Biotherapeutic Product (LBP) of its kind. Its design employs a rationally selected combination of disease-specific bacteria. Earlier Phase 2a trials demonstrated both safety and initial efficacy. Positive data emerged for both ulcerative colitis and pouchitis. Pouchitis is a rare inflammatory condition. Both diseases fall under Inflammatory Bowel Diseases (IBD). Current treatments often fail to provide lasting relief. Patients face chronic suffering. MH002 offers a novel, targeted therapeutic pathway.
MRM Health's proprietary CORAL platform defines its innovation. This technology transforms live microbial therapeutics development. It combines specific bacterial strains. A unique optimization process creates synergistic consortia. These consortia are potent. They are resilient. They are scalable. The platform enhances efficacy. It streamlines complex microbial therapy manufacturing. This provides a crucial competitive advantage. It allows for the production of complete consortia as a single drug substance. This efficiency is critical for regulatory approval and patient access.
Beyond MH002, MRM Health plans robust pipeline expansion. Two novel microbial consortia programs will rapidly advance. One targets general inflammation. The other aims to boost immune-oncology treatment efficacy. Both programs aim for Investigational New Drug (IND) approval. This signifies a readiness for human trials. The company also seeks to broaden its LBP portfolio. Strategic partnerships will facilitate this growth. These partnerships span both human and animal health sectors.
A key strategic collaboration now formalizes with Biocodex. This partnership focuses on dual objectives. First, it develops novel therapeutic assets. Second, it builds scalable manufacturing capabilities for LBPs. This alliance will generate significant additional non-dilutive funding. It further strengthens MRM Health's operational foundation. Such strategic alliances are indispensable for long-term success. They distribute risk and leverage complementary expertise.
The human microbiome represents a frontier in medicine. Trillions of microorganisms inhabit the gut. Their delicate balance profoundly impacts health. Imbalances, or dysbiosis, link to a spectrum of chronic conditions. These include autoimmune disorders, metabolic diseases, and various cancers. MRM Health meticulously leverages this scientific understanding. It engineers precise microbial consortia. These aim to restore healthy balance. They directly address disease-driving mechanisms at their source.
MRM Health positions itself at the forefront of this new medical era. Its CORAL technology has reached maturity. This enables effective development, scaling, and commercialization of live biotherapeutics. These therapies target major chronic inflammatory diseases. Millions of patients globally experience high unmet medical needs. Current treatment options often present severe side effects. They may also lose effectiveness over time. This funding empowers MRM Health to deliver significant, lasting patient impact.
The company's leadership expanded. New members joined the Board of Directors. Jean-Patrick Hennebelle represents Biocodex. Julian Zachmann represents ATHOS. Goedele Ertveldt represents SFPIM. These additions bring extensive industry experience. They offer vital strategic guidance. The expanded board will steer MRM Health. It aims to advance its pipeline robustly. It will deliver this novel class of innovative therapeutics to patients worldwide.
The global market for microbiome therapeutics experiences rapid growth. Investors increasingly recognize its transformative potential. Successful clinical trials validate the underlying science. MRM Health’s approach stands out. Its platform ensures precise, scalable, and cost-effective production. This overcomes a major hurdle in LBP development. The company is not merely exploring. It is actively building viable, commercial solutions.
This substantial funding represents a profound vote of confidence. It acknowledges years of dedicated scientific research. It unlocks the critical next phase of development. MRM Health moves significantly closer to market introduction. It strives to bring transformative therapies to those in need. The company aims for global health impact. Its vision is clear: harness the power of the microbiome for a healthier future. This is a pivotal moment for personalized medicine.